DEBUT OF IMMUNE-MEDIATED DIABETES MELLITUS SECONDARY TO IMMUNOTHERAPY IN A PATIENT WITH UROTHELIAL CANCER: CASE REPORT
DOI:
https://doi.org/10.5281/zenodo.15634907Keywords:
Ureteral Neoplasms, Transitional Cell Carcinoma, Diabetic Ketoacidosis, Diabetes Mellitus, Type 1, ImmunotherapyAbstract
A 58-year-old male patient with a single surgical kidney and a history of high-grade urothelial cancer undergoing immunotherapy and multiple comorbidities developed diabetic ketoacidosis with features of hyperosmolar syndrome after the second dose of Nivolumab. He was admitted with severe hyperglycemia, metabolic acidosis, ketonemia, hyperkalemia, and acute renal failure and was successfully treated with intensive insulin therapy and rehydration. He progressed favorably and was discharged with subcutaneous insulin and outpatient follow-up. Given that this is an underreported entity in Chile with no updated protocols, a literature review was conducted to better understand the incidence, clinical presentation, and management of this pathology.
Downloads
References
[1] Dudzińska M, Szczyrek M, Wojas-Krawczyk K, Świrska J, Chmielewska I, Zwolak A. Endocrine adverse events of nivolumab in non-small cell lung cancer patients-literature review. Cancers (Basel) [Internet]. 2020;12(8):2314. Available from: http://dx.doi.org/10.3390/cancers12082314
[2] Zekić T, Benić MS. Anti-programmed death-1 inhibitor nivolumab-induced immune-related adverse events: hepatitis, renal insufficiency, myositis, vitiligo, and hypothyroidism: a case-based review. Rheumatol Int [Internet]. 2023;43(3):559–65. Available from: http://dx.doi.org/10.1007/s00296-022-05247-5
[3] Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, et al. Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes [Internet]. 2018;67(8):1471–80. Available from: http://dx.doi.org/10.2337/dbi18-0002
[4] Mae S, Kuriyama A, Tachibana H. Diabetic ketoacidosis as a delayed immune-related event after discontinuation of nivolumab. J Emerg Med [Internet]. 2021;60(3):342–4. Available from: http://dx.doi.org/10.1016/j.jemermed.2020.09.023
[5] DailyMed - OPDIVO- nivolumab injection [Internet]. Nih.gov. [cited 2025 May 16]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394
[6] Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, et al. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. J Immunother Cancer [Internet]. 2017;5(1). Available from: http://dx.doi.org/10.1186/s40425-017-0245-2
[7] Chen X, Affinati AH, Lee Y, Turcu AF, Henry NL, Schiopu E, et al. Immune checkpoint inhibitors and risk of type 1 diabetes. Diabetes Care [Internet]. 2022;45(5):1170–6. Available from: http://dx.doi.org/10.2337/dc21-2213
[8] Zhou L, Yang S, Li Y, Xue C, Wan R. A comprehensive review of immune checkpoint inhibitor-related diabetes mellitus: incidence, clinical features, management, and prognosis. Front Immunol [Internet]. 2024;15:1448728. Available from: http://dx.doi.org/10.3389/fimmu.2024.1448728
[9] American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: Standards of care in diabetes-2025. Diabetes Care [Internet]. 2025;48(Supplement_1):S27–49. Available from: http://dx.doi.org/10.2337/dc25-S002
[10] Ishiguro A, Ogata D, Ohashi K, Hiki K, Yamakawa K, Jinnai S, et al. Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: A case report and review of 8 cases. Medicine (Baltimore) [Internet]. 2022;101(35):e30398. Available from: http://dx.doi.org/10.1097/MD.0000000000030398
[11] Gauci M-L, Laly P, Vidal-Trecan T, Baroudjian B, Gottlieb J, Madjlessi-Ezra N, et al. Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review. Cancer Immunol Immunother [Internet]. 2017;66(11):1399–410. Available from: http://dx.doi.org/10.1007/s00262-017-2033-8
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Revista Andes
This work is licensed under a Creative Commons Attribution 4.0 International License.
